Clinical Implications of HER-2 and P53 in Taxane-Based and Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer

References

1. ↵
   1. Beriwal S,
   2. Schwartz GF,
   3. Komarnicky L, et al.

   Breastconserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 2: 159-164.

   OpenUrl
2. ↵
   1. Fisher B,
   2. Brown A,
   3. Mamounas E, et al.

   Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 7: 2483-2493.

   OpenUrl
3. ↵
   1. Cleator S,
   2. Parton M,
   3. Dowsett M.

   The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002; 9: 183-195.

   OpenUrlAbstract
4. ↵
   1. Crown J,
   2. O’Leary M,
   3. Ooi WS.

   Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience. Oncologist 2004; 9: 24-32.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Petit T,
   2. Borel C,
   3. Ghnassia JP, et al.

   Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577-1581.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Petit T,
   2. Wilt M,
   3. Velten M, et al.

   Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-211.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Kariya S,
   2. Ogawa Y,
   3. Nishioka A, et al.

   Relationship between hormonal receptors, HER-2, P53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med 2005; 23: 189-194.

   OpenUrlPubMed
8. ↵
   1. Kimura M,
   2. Sano M,
   3. Fujimori M, et al.

   Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes. Anticancer Res 2008; 28: 1239-1244.

   OpenUrlAbstract/FREE Full Text
9. ↵
   1. Geisler S,
   2. Børresen-Dale AL,
   3. Johnsen H, et al.

   TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-5588.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Rahko E,
    2. Blanco G,
    3. Soini Y, et al.

    A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 2003; 39: 447-453.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Bertheau P,
    2. Turpin E,
    3. Rickman DS, et al.

    Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4: e90.

    OpenUrlCrossRefPubMed
12. ↵
    1. Bertheau P,
    2. Plassa F,
    3. Espié M, et al.

    Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852-854.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Johnson KR,
    2. Fan W.

    Reduced expression of P53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002; 22: 3197-3204.

    OpenUrlPubMedWeb of Science
14. ↵
    1. Bao H,
    2. Yu D,
    3. Wang J, et al.

    Predictive value of serum anti-P53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients. Anticancer Drugs 2008; 19: 317-323.

    OpenUrlPubMed
15. ↵
    1. Kandioler-Eckersberger D,
    2. Ludwig C,
    3. Rudas M, et al.

    TP53 mutation and P53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-56.

    OpenUrlAbstract/FREE Full Text
16. ↵
    1. Noguchi S.

    Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006; 97: 813-820

    OpenUrlCrossRefPubMed
17. ↵
    1. Reitsamer R,
    2. Peintinger F,
    3. Prokop E, et al.

    Pathological complete response rates comparing 3versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 2005; 16: 867-870.

    OpenUrlCrossRefPubMed